familial Prostate cancer

Germline mutations in the RNASEL gene have been identified for an autosomal dominant form of hereditary prostate cancer (OMIM: 601518). Several other loci which confer susceptibility to prostate cancer have also been mapped. OMIM: 176807

Also Known As:

Networked: 103 relevant articles (0 outcomes, 21 trials/studies)

Disease Context: Research Results

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer)
2.	Neoplasms (Cancer)
3.	Skin Neoplasms (Skin Cancer)
4.	Melanoma (Melanoma, Malignant)
5.	Infections

Experts

1.	Isaacs, William B: 9 articles (06/2014 - 11/2002)
2.	Silverman, Robert H: 9 articles (01/2011 - 12/2002)
3.	Cooney, Kathleen A: 8 articles (06/2014 - 03/2003)
4.	Xu, Jianfeng: 7 articles (12/2012 - 11/2002)
5.	Zheng, S Lilly: 6 articles (12/2012 - 01/2003)
6.	Matsui, Hiroshi: 6 articles (01/2008 - 05/2003)
7.	Nakata, Seiji: 6 articles (01/2008 - 05/2003)
8.	Nakazato, Haruki: 6 articles (01/2008 - 05/2003)
9.	Ohtake, Nobuaki: 6 articles (01/2008 - 05/2003)
10.	Okugi, Hironobu: 6 articles (01/2008 - 05/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to familial Prostate cancer:

1.	AndrogensIBA 01/01/2006 - "Genetic polymorphisms of the genes involved in androgen metabolism and signaling were significantly associated with familial prostate cancer risk. " 01/01/2006 - "Association of the polymorphisms of genes involved in androgen metabolism and signaling pathways with familial prostate cancer risk in a Japanese population." 06/01/2004 - "In addition to the expected role of androgens and their receptors in facilitating the development of PCa, mutations in a growing number of candidate hereditary prostate cancer loci and genes, such as RNASEL and MSR1, have been detected, suggesting that defects in critical pathways involving DNA damage response, apoptosis and innate immunity may have a particularly important role in the initiation of PCa. " 10/01/1999 - "Familial prostate cancer (p = 0.001), higher T stage (p<0.001), higher initial PSA (p<0.001), higher biopsy Gleason score (p<0.001) and use of androgen deprivation (p = 0.001) were independent predictors of biochemical failure and all other factors, including race, were not (p = 0.46). " 01/15/1999 - "Familial prostate cancer: outcome following radiation therapy with or without adjuvant androgen ablation."
2.	2-5A-dependent ribonuclease (RNase L)IBA 02/25/2003 - "Genetics studies from several laboratories in the U.S., Finland, and Israel, support the recent identification of the RNase L gene, RNASEL, as a strong candidate for the long sought after hereditary prostate cancer 1 (HPC1) allele. " 05/01/2010 - "The search for viral causes of these syndromes was reignited by the finding that RNase L activity was low in hereditary prostate cancer and some CFS patients. " 11/01/2008 - "Forty percent (8/20) of familial prostate cancer patients homozygous for a mutation in RNase L (R462Q) were positive for XMRV, while the virus was rarely (1/66) detected in familial prostate cancer patients heterozygous for R462Q or carrying the wild type allele. " 10/01/2008 - "RNase L gene has been identified as HPC1 (Hereditary Prostate Cancer 1) gene. " 10/01/2007 - "Recently, RNase L was identified as the hereditary prostate cancer 1 gene. "
3.	Prostate-Specific Antigen (Semenogelase)IBA 09/08/2010 - "Effects of prostate-specific antigen testing on familial prostate cancer risk estimates." 09/01/2006 - "Preoperatively prostate specific antigen was higher in patients with hereditary prostate cancer than in the other 2 groups (p = 0.04). " 09/01/2006 - "We examined the impact of familial and hereditary prostate cancer treatment in the prostate specific antigen era. " 01/01/1998 - "Significance of measurement of prostate specific antigen (PSA) in familial prostate cancer lines." 09/01/2003 - "In this pilot study, we set out to determine the proportion of unaffected men whose families are participating in a study of hereditary prostate cancer who have been tested for prostate cancer with serum prostate-specific antigen (PSA) measurement and digital rectal examination (DRE). "
4.	DNA (Deoxyribonucleic Acid)IBA 12/01/2001 - "An even greater proportion of African-American families have shown linkage to HPC 1. Therefore, investigators at the National Human Genome Research Institute [NHGRI] in collaboration with Howard University and a predominantly African-American group of urologists established the African-American Hereditary Prostate Cancer (AAHPC) Study Network to confirm the suggested linkage of HPC in African Americans with a gene on Chromosome 1. Blood samples from recruited families were sent to Howard University for extraction of DNA. " 04/01/2001 - "Therefore, investigators at the National Human Genome Research Institute (NHGRI) in collaboration with Howard University and a predominantly African-American group of urologists established the African-American Hereditary Prostate Cancer (AAHPC) Study Network to confirm the suggested linkage of HPC in African Americans with a gene on Chromosome 1. Blood samples from recruited families were sent to Howard University for extraction of DNA. " 05/14/2008 - "There are many splice variants, the best characterized of which are MUC1/1 and MUC1/2 which are determined by a SNP (rs4072037, 3506G>A).Blood DNA from the general population, BPH, sporadic and hereditary prostate cancer subjects were genotyped for the rs4072037 SNP. " 08/15/2000 - "Blood DNA from affected individuals in 38 prostate cancer clusters was analyzed for germ-line mutations in BRCA1 and BRCA2 to assess the contribution of each of these genes to familial prostate cancer. " 02/15/2006 - "These include the ELAC2 (HPC2), MSR1, and RNASEL (HPC1) genes that have germline mutations in familial prostate cancer; AR, ATBF1, EPHB2 (ERK), KLF6, mitochondria DNA, p53, PTEN, and RAS that have somatic mutations in sporadic prostate cancer; AR, BRCA1, BRCA2, CHEK2 (RAD53), CYP17, CYP1B1, CYP3A4, GSTM1, GSTP1, GSTT1, PON1, SRD5A2, and VDR that have germline genetic variants associated with either hereditary and/or sporadic prostate cancer; and ANXA7 (ANX7), KLF5, NKX3-1 (NKX3.1), CDKN1B (p27), and MYC that have genomic copy number changes affecting gene function. "
5.	Ribonucleases (Ribonuclease)IBA 12/15/2011 - "In turn, 2-5A activates latent ribonuclease (RNaseL), a candidate hereditary prostate cancer gene. " 12/10/2005 - "The RNASEL (encoding ribonuclease L) gene Glu265X mutation has been implicated in familial prostate cancer, and an association between the RNASEL Arg462Gln variant and sporadic and familial prostate cancer, has also been suggested. " 12/01/2002 - "RNASEL (encoding ribonuclease L) has recently been proposed as a candidate for the hereditary prostate cancer (HPC1) gene. " 12/01/2003 - "Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer." 12/01/2003 - "The ribonuclease L (RNase L) gene has been reported as the putative hereditary prostate cancer gene located at HPC1. "
6.	protein C activator peptideIBA 09/01/2002 - "A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer." 02/01/2001 - "Those results suggest that PCaP is the most frequent known locus predisposing to hereditary prostate cancer cases from families from south and west Europe." 10/01/2000 - "Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer." 02/01/2000 - "Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer." 02/01/2001 - "To date four prostate cancer predisposing loci have been mapped: HPC1 (Hereditary Prostate Cancer 1) on 1q24-25, PCaP (Predisposing for Cancer Prostate) on 1q42.2-43, CAPB (Cancer Prostate and Brain) on 1p36, and HPCX on Xq27-28. "
7.	Scavenger Receptors (Scavenger Receptor)IBA 05/01/2004 - "The macrophage scavenger receptor 1 (MSR1) gene on chromosome 8p22 was recently reported as a candidate gene for hereditary prostate cancer (HPC). " 10/01/2003 - "The macrophage scavenger receptor 1 gene (MSR1) was recently identified as a candidate susceptibility gene for hereditary prostate cancer and as a risk factor for sporadic prostate cancer. " 01/01/2003 - "Rare germline mutations of macrophage scavenger receptor 1 (MSR1) gene were reported to be associated with prostate cancer risk in families with hereditary prostate cancer (HPC) and in patients with non-HPC (Xu et al. 2002). " 11/01/2004 - "Genetic studies have identified RNASEL, encoding an interferon inducible ribonuclease, and MSR1, encoding subunits of the macrophage scavenger receptor, as candidate inherited susceptibility genes for familial prostate cancer. "
8.	InterferonsIBA 02/05/2007 - "Many genes targeted by their interaction were involved in type I and II interferon signaling and several were functionally related to hereditary prostate cancer genes. " 11/01/2004 - "Genetic studies have identified RNASEL, encoding an interferon inducible ribonuclease, and MSR1, encoding subunits of the macrophage scavenger receptor, as candidate inherited susceptibility genes for familial prostate cancer. " 01/01/2016 - "The type I/III interferon (IFN)-inducible 2'-5'- oligoadenylate synthetase (OAS)/endoribonuclease L (RNase L) is a classical innate immune pathway that has been implicated in antiviral and antibacterial defense and also in hereditary prostate cancer. " 12/15/2004 - "The hereditary prostate cancer 1 (HPC1) allele maps to the RNASEL gene encoding a protein (RNase L) implicated in the antiviral activity of interferons. "
9.	Untranslated Regions (Untranslated Region)IBA 12/01/2012 - "In this study, 94 unrelated familial prostate cancer cases from the University of Michigan Prostate Cancer Genetics Project (n = 54) and Johns Hopkins University (n = 40) were subjected to targeted next-generation sequencing of the exons, including UTRs, of NBN. " 06/01/2014 - "We performed targeted next generation sequencing to analyze 2009 exons from 202 genes in a candidate linkage region on chromosome 17q21-22 using 94 unrelated familial prostate cancer cases from the University of Michigan Prostate Cancer Genetics Project (n=54) and Johns Hopkins University (n=40) including the exons and UTRs of SPOP. "
10.	EnzymesIBA 06/15/2005 - "These results also shed some light on clinical observations suggesting that alterations in genes coding for 3beta-hydroxysteroid dehydrogenases (the enzymes responsible for 3beta-Adiol formation) are strongly correlated with hereditary prostate cancer." 05/01/2007 - "In this study, we systematically tested the hypothesis that common genetic variations for those enzymes involved in the androgen and estrogen metabolic pathways increase risk for sporadic and familial prostate cancer. "

Therapies and Procedures

1.	Therapeutics 04/04/2021 - "Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention." 01/01/2009 - "This is the first study to examine the relationship of familial prostate cancer and outcomed in men treated with brachytherapy alone or in combination therapy. " 12/01/2017 - "We surveyed 4719 PC survivors from the German multicenter prospective database "Familial Prostate Cancer." We evaluated the association of PC-related anxiety (MAX-PC) with sociodemographic characteristics, family history of PC, global health status/quality of life (EORTC QLQ-C30), depression and anxiety (PHQ-2; GAD-2), latest PSA level, time since radical prostatectomy, and current therapy. " 01/01/2017 - "We identified 10,310 patients after radical prostatectomy without neoadjuvant or adjuvant therapy between 1979 and 2015 in the prospective German Familial Prostate Cancer database. " 06/01/2002 - "Distributions of tumor grade, symptoms at diagnosis and initial therapy were similar in hereditary prostate cancer cases and controls. "
2.	Chemoprevention 04/01/2001 - "African American men and hereditary/familial prostate cancer: Intermediate-risk populations for chemoprevention trials." 04/01/2001 - "A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues."
3.	Prostatectomy (Retropubic Prostatectomy) 11/15/2021 - "In all, 2417 survivors from the multicenter German Familial Prostate Cancer Database completed the Fear of Progression Questionnaire-Short Form on average 7 years (T1 in 2010) after radical prostatectomy and at follow-up 9 years later (T2 in 2019). " 07/01/2021 - "Participants in the German Familial Prostate Cancer database diagnosed from 1994 to 2019 with (1) low risk (clinical T1c-T2a, biopsy Gleason Grade Group (GGG) 1, PSA < 10 ng/ml), (2) Gleason 6 FIR (clinical T1c-T2a, GGG 1, PSA 10-20 ng/ml), and (3) Gleason 3 + 4 FIR (clinical T1c-T2a, GGG 2, PSA < 10 ng/ml) PCa who were subsequently treated with radical prostatectomy (RP) were analysed for upgrading, defined as postoperative GGG 3 tumour or upstaging, defined as pT3-pT4 or pN1 disease at RP. " 06/01/2003 - "Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases." 06/01/2003 - "463 German patients with familial prostate cancer who underwent radical prostatectomy were stratified according to several epidemiological criteria: (1). " 06/01/2003 - "Association between the clinical presentation and epidemiological features of familial prostate cancer in patients selected for radical prostatectomy."
4.	Drug Therapy (Chemotherapy) 12/01/2016 - "In this study we evaluated the prevalence of PPM1D mutations in white blood cells (WBC) of 462 patients with early-onset and/or familial/hereditary prostate cancer (PrCa) by sequencing the coding region of exon 6. Two truncating mutations were found in two patients (0.4%), both treated with androgen-ablation therapy but no chemotherapy prior to blood collection. "
5.	Brachytherapy 01/01/2009 - "This is the first study to examine the relationship of familial prostate cancer and outcomed in men treated with brachytherapy alone or in combination therapy. " 01/01/2009 - "To determine the impact familial prostate cancer has on prognosis in men treated with brachytherapy for clinically localized prostate cancer. "